ACET - Adicet Bio, Inc.
After hours:
Chart Events
Fast Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 5.35 |
| Open | 5.34 |
| Bid | 5.12 x 800 |
| Ask | 5.86 x 800 |
| Day's Range | 5.24 - 5.48 |
| 52 Week Range | 4.61 - 21.87 |
| Volume | |
| Avg. Volume | 469,912 |
| Market Cap | 225.957M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.48 |
| Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.56 |
Fair Value
Related Research
Business WireAdicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference
REDWOOD CITY, Calif. & BOSTON, June 01, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York.
Business WireAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON, May 31, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on May 31, 2023.
Business WireAdicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
REDWOOD CITY, Calif. & BOSTON, May 18, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced preclinical data highlighting ADI-270, an armored allogeneic "off-the-shelf" gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place from May 16-20, 2023,
Business WireAdicet Bio to Present at the 2023 JMP Securities Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON, May 09, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 JMP Securities Life Sciences Conference being held from May 15-16, 2023 in New York.
Business WireAdicet Reports First Quarter 2023 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON, May 09, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023.
InvestorPlace7 Biotech Stocks With Huge Return Potential for Long-Term Investors
Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can’t just introduce health-related products directly to the market. Instead, they must undergo intensive clinical tests to ensure broader public safety. During these processes, plenty of things can go wrong, thus introducing volatility to the space. Still, investors who want to maximize the return potential of their speculation-earmarked funds should consider
Simply Wall St.Adicet Bio, Inc.'s (NASDAQ:ACET) Price Is Out Of Tune With Revenues
It's not a stretch to say that Adicet Bio, Inc.'s ( NASDAQ:ACET ) price-to-sales (or "P/S") ratio of 9.6x right now...
Business WireAdicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif. & BOSTON, April 13, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 20, 2023.
TipRanksDown More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound
Stock markets offer one of the great paradoxes of life – that when conditions grow difficult and prices fall, opportunities for profit will appear. For investors, it’s a chance to cash in – after a proper look into the nuts and bolts behind a market decline. As always with stocks, informed decisions are the most likely to pan out. To jumpstart that due diligence, we can check in with Wall Street’s analysts. These are the pros, the equity experts who’ve built their reputations learning and analyz
Business WireAdicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif. & BOSTON, March 15, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022.
InvestorPlace7 Biotech Stocks That Could Be the Next Big Thing
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment. Nevertheless, they could yield tremendous profitability if they come through. Another factor that benefits high-risk, high-reward biotech stocks centers on the underlying sector’s permanent
Business WireAdicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
REDWOOD CITY, Calif. & BOSTON, March 09, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, and Nick Harvey, Chief Financial Officer, will participate in the 2023 Jefferies Biotech on the Bay Summit being held March 16-17, 2023.
- Simply Wall St.
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Business Wire
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference
REDWOOD CITY, Calif. & BOSTON, February 01, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference being held from February 8-9, 2023.
- Simply Wall St.
Shareholders in Adicet Bio (NASDAQ:ACET) have lost 49%, as stock drops 22% this past week
Investors can approximate the average market return by buying an index fund. While individual stocks can be big...
Business WireAdicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
REDWOOD CITY, Calif. & BOSTON, December 10, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data from the Company’s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL. The Company believes these data continue to support the potential of Adicet’s investigational gamma delta CAR T cell therapy to pro
- Business Wire
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
REDWOOD CITY, Calif. & BOSTON, December 02, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.
Business WireAdicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
REDWOOD CITY, Calif. & BOSTON, November 30, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022.
Business WireAdicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
REDWOOD CITY, Calif. & BOSTON, November 29, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer. Dr. Boman will spearhead Adicet’s regulatory strategy to further advance existing and new pipeline opportunities for the Company’s gamma delta T cell platform.
- Simply Wall St.
Adicet Bio Third Quarter 2022 Earnings: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)
Adicet Bio ( NASDAQ:ACET ) Third Quarter 2022 Results Key Financial Results Net loss: US$22.0m (loss widened by 57...
Business WireAdicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON, November 08, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2022.
Business WireAdicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
REDWOOD CITY, Calif. & BOSTON, November 07, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that positive preclinical data from four new pipeline programs will be featured at poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on November 10-11, 2022.
Business WireAdicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
REDWOOD CITY, Calif. & BOSTON, November 03, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that an abstract detailing updated safety and efficacy data from the Company’s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL) was made available as part of the 64th American Society of Hematology (ASH) Annual Meetin
Business WireAdicet Bio to Present at the 2022 Jefferies London Healthcare Conference
REDWOOD CITY, Calif. & BOSTON, November 01, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2022 Jefferies London Healthcare Conference being held from November 15-17, 2022 in London.
- Simply Wall St.
Calculating The Intrinsic Value Of Adicet Bio, Inc. (NASDAQ:ACET)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Adicet Bio, Inc...